[go: up one dir, main page]

GB202218388D0 - GP130 antigen-binding molecules - Google Patents

GP130 antigen-binding molecules

Info

Publication number
GB202218388D0
GB202218388D0 GBGB2218388.3A GB202218388A GB202218388D0 GB 202218388 D0 GB202218388 D0 GB 202218388D0 GB 202218388 A GB202218388 A GB 202218388A GB 202218388 D0 GB202218388 D0 GB 202218388D0
Authority
GB
United Kingdom
Prior art keywords
antigen
binding molecules
molecules
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2218388.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VVB Bio Pte Ltd
Original Assignee
VVB Bio Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VVB Bio Pte Ltd filed Critical VVB Bio Pte Ltd
Priority to GBGB2218388.3A priority Critical patent/GB202218388D0/en
Publication of GB202218388D0 publication Critical patent/GB202218388D0/en
Priority to EP23822257.4A priority patent/EP4630453A1/en
Priority to KR1020257022627A priority patent/KR20250131844A/en
Priority to JP2025532860A priority patent/JP2026501115A/en
Priority to PCT/EP2023/084528 priority patent/WO2024121233A1/en
Priority to CN202380092139.0A priority patent/CN120569406A/en
Priority to AU2023389042A priority patent/AU2023389042A1/en
Priority to MX2025006646A priority patent/MX2025006646A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB2218388.3A 2022-12-07 2022-12-07 GP130 antigen-binding molecules Ceased GB202218388D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB2218388.3A GB202218388D0 (en) 2022-12-07 2022-12-07 GP130 antigen-binding molecules
EP23822257.4A EP4630453A1 (en) 2022-12-07 2023-12-06 Gp130 antigen-binding molecules
KR1020257022627A KR20250131844A (en) 2022-12-07 2023-12-06 GP 130 antigen-binding molecule
JP2025532860A JP2026501115A (en) 2022-12-07 2023-12-06 Gp130 antigen binding molecule
PCT/EP2023/084528 WO2024121233A1 (en) 2022-12-07 2023-12-06 Gp130 antigen-binding molecules
CN202380092139.0A CN120569406A (en) 2022-12-07 2023-12-06 Gp130 antigen binding molecules
AU2023389042A AU2023389042A1 (en) 2022-12-07 2023-12-06 Gp130 antigen-binding molecules
MX2025006646A MX2025006646A (en) 2022-12-07 2025-06-06 Gp130 antigen-binding molecules

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2218388.3A GB202218388D0 (en) 2022-12-07 2022-12-07 GP130 antigen-binding molecules

Publications (1)

Publication Number Publication Date
GB202218388D0 true GB202218388D0 (en) 2023-01-18

Family

ID=84926725

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2218388.3A Ceased GB202218388D0 (en) 2022-12-07 2022-12-07 GP130 antigen-binding molecules

Country Status (8)

Country Link
EP (1) EP4630453A1 (en)
JP (1) JP2026501115A (en)
KR (1) KR20250131844A (en)
CN (1) CN120569406A (en)
AU (1) AU2023389042A1 (en)
GB (1) GB202218388D0 (en)
MX (1) MX2025006646A (en)
WO (1) WO2024121233A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571513A (en) * 1995-05-31 1996-11-05 The Board Of Regents Of The University Of Oklahoma Anti-gp130 monoclonal antibodies
EP2718322B1 (en) 2011-06-06 2018-08-08 Novo Nordisk A/S Therapeutic antibodies
GB201522186D0 (en) 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
GB201716733D0 (en) 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
AU2018390811A1 (en) 2017-12-18 2020-07-02 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
CN113677706B (en) 2019-01-21 2025-05-02 新加坡保健服务私人有限公司 Treatment of hepatotoxicity
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
AU2020268619A1 (en) 2019-05-03 2021-12-16 National University Of Singapore Treatment and prevention of metabolic diseases
GB202017244D0 (en) 2020-10-30 2020-12-16 Nat Univ Singapore Methods to extend health-span and treat age-related diseases

Also Published As

Publication number Publication date
EP4630453A1 (en) 2025-10-15
JP2026501115A (en) 2026-01-14
MX2025006646A (en) 2025-09-02
KR20250131844A (en) 2025-09-03
CN120569406A (en) 2025-08-29
WO2024121233A1 (en) 2024-06-13
AU2023389042A1 (en) 2025-07-03

Similar Documents

Publication Publication Date Title
SG11202105302PA (en) Dll3-targeting multispecific antigen-binding molecules and uses thereof
SG11202102882YA (en) Antigen-binding molecule comprising altered antibody variable region
SG11202009515RA (en) Vista antigen-binding molecules
GB202311050D0 (en) GP130 antigen-binding molecules
IL290299A (en) Multispecific antigen-binding molecules for cell targeting and uses thereof
GB201814562D0 (en) Vista antigen-binding molecules
IL325040A (en) Uses of dll3-targeting multispecific antigen-binding molecules
GB202218388D0 (en) GP130 antigen-binding molecules
EP3928790A4 (en) CD3 ANTIGEN-BINDING FRAGMENT AND ITS USE
GB201709970D0 (en) Bispecific antigen-binding molecules
IL292698A (en) N-terminal scfv multispecific binding molecules
SG11202104264TA (en) Claudin-6 targeting multispecific antigen-binding molecules and uses thereof
IL276253B1 (en) Bispecific antigen-binding molecules and methods of use
IL286918A (en) Bispecific antibody
EP4339213A4 (en) ANTIGEN-BINDING MOLECULES
IL325163A (en) Cd40 x cd40 bispecific antigen-binding molecules and uses thereof
IL290050A (en) Bispecific antibody
IL318557A (en) Bispecific anti-c-kit and anti-cd203c antigen-binding molecules and uses thereof
GB202310962D0 (en) GP130 antigen-binding molecules
GB202408044D0 (en) gp130 antigen-binding molecules
IL284703A (en) Anandamide compounds
IL317637A (en) Anti-steap1 antigen-binding molecules and uses thereof
CA3274782A1 (en) Gp130 antigen-binding molecules
HK40126861A (en) Gp130 antigen-binding molecules
GB2592920B (en) Removable spacer

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)